Virbac : Resilient Q2 2020, greater than expected contribution from Sentinel, our 2020 profit estimate upgraded, target price raised to € 210 vs € 192
>Q2, down 64% and -3.3% cc, proved somewhat resilient - Q2 revenues were down 6.4% year-on-year (-3.3% cc, negative forex effect in Latin America and Asia-Pacific). At end-June, revenues stood at € 478,3m, up 3%. All regions reported growth to end June, reflecting the resilience of the sector and different epidemic stages across regions. Europe and Latin America drove H1 growth: +5.7% (+5.5% cc) and +1.3% (+9.3% cc) respectively, with countries worse hit by the ...Virbac is an independent veterinary pharmaceutical laboratory. Co. develops and provides veterinarians and farmers with medicines and vaccines that improve the health of food producing animals. Co. markets a range of products designed for pets and livestock. It offers seven types of products for companion animals (Parasiticides, Immunology, Antibiotics/dermatology, Specialties, Equine, Specialized pet food and Other products), and four types of products for food producing animals (Bovine parasiticides, Bovine products (excluding parasiticides), Pig/poultry antibiotics and Other products). Co. markets its products in the ethical (veterinarian) and OTC markets.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.